Navigation Links
The American Society for Microbiology honors Alison Criss
Date:9/13/2011

Alison K. Criss, Ph.D., University of Virginia, Charlottesville, has been chosen by the American Society for Microbiology (ASM) to receive a 2011 ICAAC Young Investigator Award for her outstanding research on bacterial pathogenesis. Sponsored by Merck, U.S. Human Health Division, this award recognizes an early career scientist for research excellence in microbiology and infectious diseases.

Dr. Criss received her Ph.D. from Harvard University and completed her postdoctoral fellowship at Northwestern University. She was nominated by her postdoctoral advisor, H. Steven Seifert, Fellow of the American Academy of Microbiology, who describes Dr. Criss as an "extremely intelligent, insightful, diligent, meticulous, hard working person who tackles problems head-on."

Dr. Criss is currently an Assistant Professor in the Department of Microbiology at the University of Virginia, where she studies the interactions of Neisseria gonorrhoeae with PMNs in her laboratory at the University of Virginia. A supporter of her nomination, Joanna Goldberg, Academy Fellow from the University of Virginia, describes Dr. Criss as "truly a rising young star [who] has a very professional and enthusiastic manner that serves to engage and inspire students to perform at the best of their ability."

Dr. Criss' research focuses on the interplay between bacterial pathogens and host cells at mucosal surfaces. Her graduate work explored the regulation of Salmonella pathogenesis by Rho and ARF family GTPases in polarized epithelial cells. As a postdoctoral fellow at Northwestern, Dr. Criss investigated the robust mechanisms by which N. gonorrhoeae avoids immune recognition and clearance. N. gonorrhoeae evades humoral immunity by varying its surface components, including antigenic variation of the type IV pilus. She used high-throughput DNA sequencing to show that pilin antigenic variation occurs at the highest frequency of any known pathogenic gene conversion system and produces a diverse repertoire of pilin proteins, as observed during human disease. N. gonorrhoeae also survives exposure to neutrophils in gonorrheal secretions, for reasons that are poorly understood. Using a primary human neutrophil infection model, Dr. Criss demonstrated that N. gonorrhoeae suppresses neutrophil production of reactive oxidative species and encodes gene products that confer resistance to neutrophils' non-oxidative antimicrobial activities. Her laboratory at the University of Virginia is elucidating the molecular and cellular interactions between N. gonorrhoeae and neutrophils, with the goals of identifying the antimicrobial activities neutrophils direct against N. gonorrhoeae and the bacterial defenses that subvert them.

William Shafer, Academy Fellow from Emory University and supporter of Dr. Criss' nomination, says "I have been most favorably impressed by the rigor that Dr. Criss applies to her work, the depth of her thought processes, and her willingness to freely exchange ideas and reagents She has performed the most convincing (and elegant) work to date that shows N. gonorrhoeae can resist intraleukocytic killing by human PMNs."


'/>"/>

Contact: Garth Hogan
ghogan@asmusa.org
American Society for Microbiology
Source:Eurekalert

Related biology news :

1. News from the October 2008 Journal of the American Dietetic Association
2. American Chemical Societys Weekly PressPac -- Sept. 24, 2008
3. Nanotech and synbio: Americans dont know whats coming
4. American Chemical Societys Weekly PressPac
5. American College of Medical Genetics receives $13.5M NIH contract
6. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
7. American Chemical Society Weekly PressPac Oct. 15, 2008
8. Scientists map soils on an extinct American volcano
9. Indiana University research at American Public Health Association meeting
10. North American environmental commission launches trinational vaquita conservation plan
11. News from the November 2008 Journal of the American Dietetic Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... and CEO, Jim Joyce . In ... Saturday, Bill Gates warned world leaders that ... nuclear weapons. Mr. Gates expressed his concern, which is ... scientific terrorists have access to the necessary tools to ...
(Date:2/24/2017)... KONG, Feb. 24, 2017 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its unaudited financial results for the third ... ended December 31, 2016. Third Quarter of ... third quarter of fiscal 2017 increased by 18.6% to ...
(Date:2/24/2017)... 2017  VWR Corporation (NASDAQ: VWR), the leading global independent ... customers, today reported its financial results for the fourth quarter ... 4Q16 record quarterly net sales of ... organic basis. 4Q16 EMEA-APAC segment ... while the Americas net sales increased 2.5%, or down 0.9% ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
Breaking Biology Technology: